Price
Target price
€1.67
€1.67
1.370%
0.023
1.370%
€4.39
23.04.24 / Tradegate
WKN: A3C4ZC / Symbol: XERS / Name: Xeris Biopharma / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xeris Biopharma Holdings Inc. Stock
There is an upward development for Xeris Biopharma Holdings Inc. compared to yesterday, with an increase of €0.023 (1.370%).
Currently there is a rather positive sentiment for Xeris Biopharma Holdings Inc. with 4 Buy predictions and 0 Sell predictions.
Based on the current price of 1.67 € the target price of 4 € shows a potential of 139.81% for Xeris Biopharma Holdings Inc. which would more than double the current price.
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 1.370% | -1.302% | -14.462% | -15.758% | -22.778% | -49.424% | - |
| Ardelyx Inc. | 3.750% | -5.482% | -15.972% | 32.578% | 3.218% | -12.905% | - |
| Salarius Pharmaceuticals Inc. | 4.250% | -0.935% | -18.462% | -68.120% | -23.604% | -98.261% | -99.994% |
| Brainstorm Cell | 1.170% | -0.896% | -1.485% | -81.710% | 114.440% | -80.717% | - |
Comments
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $5.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its price target lowered by analysts at Piper Sandler from $5.00 to $4.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is now covered by analysts at Craig Hallum. They set a "buy" rating and a $4.50 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat